All Data

背景：糖尿病患者における聴覚障害の有病率は有意に高く、その予防法の開発が望まれている。 目的：本研究では、糖尿病マウスに対するエイコサペンタエン酸（EPA）投与による早期難聴の予防効果を検討した。 方法：糖尿病モデルとしてTSOD（Tsumura, Suzuki, Obese Diabetes）マウスを、コントロールとしてTSNO（Tsumura, Suzuki, Non Obesity）マウスを使用した。TSNO群とTSOD（EPA-）群（ひまわり油投与）、TSOD（EPA＋）群（EPA投与）の3 群に分けた。聴性脳幹反応（ABR）を測定し、蝸牛を組織学的に評価した。 結果：TSOD（EPA＋）群はTSOD（EPA-）群に比べ、閾値の上昇が小さい傾向を認めた。TSOD（EPA+）群では、生後11 ヶ月から14 ヶ月にかけて、4kHzでのABR 閾値がTSOD（EPA-）群よりも有意に低かった。TSOD（EPA-）群では、血管条の毛細血管内腔の狭小化と蝸牛軸における血管壁の肥厚が観察された。 結論：TSOD マウスに対するEPA 投与による蝸牛血管の動脈硬化の抑制は、加齢に伴う早期難聴を抑制することが示唆された。

方法： 本研究は圧縮センシングを用いた自由呼吸下での多相ダイナミックEOB-MRIを撮像された96人の患者を対象とした。多相ダイナミック撮像として自由呼吸下で11秒毎に1相を5分間、脂肪抑制T1強調画像を撮像し、単純1相と造影28相を撮像した。造影剤投与後20分後に肝細胞相を撮像し、30相目とした。ROI: region of intensityを肝右葉に2つ、左葉に1つを脈管を避けながら可能な限り大きく設定した。3つのROIの信号強度の平均値をそれぞれの時相の信号強度とした。 以下の増強効果のパラメータについて評価した。 CER (contrast enhancement ratio) CERy-x: (SIy -SIx)/SIx (x相目からy相目)とし、 CER4-pre：動脈相 CER7-5：門脈相から動脈相にかけて CER7-pre：門脈相 CER28-pre：5分早期肝細胞相 CER28-7：門脈相から5分早期肝細胞相 CERHBP-pre：20分肝細胞相 GRL (gradient of regression line)：回帰曲線の傾き GRLy-x: x相目からy相目とし、 GRL4-2：動脈相での傾き GRL7-4 ：門脈相での傾き GRL 7-2 ：動脈相、門脈相にかけての傾き GRL 28-7：門脈相から早期肝細胞相での傾き 先行研究によると、肝実質の線維化の重症度(F0-F2 vs F3-F4)に基づいてCERHBP-preでcut off値を0.703として肝細胞相での増強効果がinsufficient HBP enhancement groupとsufficient HBP enhancement groupに分けれるとしている。CERHBP-pre<0.703またはCERHBP-pre>0.703により患者を2群に分け、CERy-x、GRLy-xについて検討した。 上記に加えて年齢、性別、総ビリルビン、プロトロンビン時間、アルブミン、eGFRについても、この2群間で比較した(ウィルコクソンの順位和検定)。 肝細胞相の増強効果に対する影響の大きさを調べるためにノンパラメトリック検定も用いられた(スピアマンの順位相関係数)。 結果： 動脈相(CER4-pre、GRL4-2)に関する結果として、これらはsufficient HBP enhancement groupがinsufficient HBP enhancement groupの間に有意差を認めなかった。 動脈門脈相(1相目～7相目)に関する結果としては、CER7-preはsufficient HBP enhancement groupがinsufficient HBP enhancement groupより有意に高い値となった(0.55 vs 0.44, p<0.001)。CER4-pre、GRL4-2、Gradient7-4、Gradient7-2では2群間に有意差は見られなかった。 5分後の早期肝細胞相(1相目～28相目)に関する結果としては、CER28-pre、CER28-7、GRL28-7においてsufficient HBP enhancement groupがinsufficient HBP enhancement groupより有意に高い値となった(0.64 vs 0.47, 0.10 vs 0.03, 1.27 vs 0.27、すべてp<0.001)。 血液データ(総ビリルビン、プロトロビン時間、アルブミン、eGFR)においても2群間で有意差が認められた(p=0.004-0.049)。CER7-pre、CER28-pre、CER28-7、GRL28-7の各パラメータは血液データのパラメータよりも相関係数が高かった。 CER28-preが最も相関係数が高かった(0.838)。 考察： 動脈相では2群間(sufficient HBP enhancement groupとinsufficient HBP enhancement group)に有意差を認めず、門脈相のパラメータでは有意差が見られた。機序としては推測になってしまうが、肝の線維化の進行に伴い門脈血流は低下しやすいが、動脈血流は比較的保たれることが原因であろうか。 また、肝細胞相の信号強度は、血液データなどによって得られた肝機能を示す数値と相関することはこれまでにも報告されてきた。肝機能が良好であるほど、肝細胞がEOBを取り込みやすいためとされる。 本研究では腎機能と肝細胞相の信号強度とにも相関が見られたが、腎機能が低い症例の方がより肝排泄の割合が増えるからと思われた。 本研究のように、ダイナミック撮像中に得られるパラメータが肝細胞相における肝実質の信号強度と相関することを報告した研究はこれまでになかった。 CER7-pre、CER28-pre、CER28-7、GRL28-7の各パラメータは、いずれも血液データのパラメータよりも相関係数が高かった。 本研究のようにダイナミック撮像中に得られたパラメータを用いれば、血液データよりも高い精度で肝実質の信号強度を予測することができる。 これにより、肝細胞相の撮像タイミングを症例により短縮できることが期待される。 結語： 圧縮センシングを用いた自由呼吸下でのEOB-MRIのダイナミック撮像おいて、肝実質の信号強度の変化を連続データとして捉えることにより得られたパラメータは、肝細胞相での肝実質の信号強度と強い相関を示す。これにより、肝細胞相の撮像タイミングを症例により短縮できることが期待される。

間葉系幹細胞（MSC）は、再生医療において有用な細胞である。MSCの培養工程の初期に、組織から抽出した単核球を培養容器に播種し、MSCの単離を行う。単離工程において、単核球の播種密度を最適化することで、単離後のMSCの収量や分化能が向上することが報告されている。しかし、単核球の播種密度がMSCの品質に影響する機構は明らかになっていない。 我々はその機構を明らかにする為、ヒト骨髄単核球を様々な播種密度（4.0×104、1.25×105、2.5×105、6.3×105、1.25×106cells/cm2）で培養し、単核球の播種密度とMSCのコロニー形成過程との関係を解析した。播種密度が高い条件（6.3×105、1.25×106cells/cm2）では、培養容器に接着したMSC同士の距離が小さく、互いの増殖スペースが制限される為、早期に高密度に達した。一方、低い播種密度（4.0×104、1.25×105 cells/cm2）では、MSCは単一細胞由来のコロニーを形成し、コロニーの直径や密度は様々な形態を示した。コロニーを継時観察したところ、高い増殖能力を持つMSCは、培養時間の経過に伴い、全体におけるその割合が増加した。それに対して、増殖能力が低いMSCは肥大化し、老化が進行した。老化細胞は剥離処理の時間を調整することで除去できることを見出した。単核球の播種密度が低い条件で、上記機構により、増殖能が高いMSCの純度が向上することが明らかになった。この機構をもとに単離工程のパラメータを最適化し、得られたMSCの増殖能と分化能を評価した。単核球の播種密度が高い条件（1.25×106cells/cm2）と比較し、最適化した条件（播種密度：1.25×105cells/cm2）から得られたMSCは、高い増殖能を示し、骨以外の脂肪や軟骨への分化能が有意に上昇した。 本研究により、高品質なMSCの純度を向上させる方法として、（1）単一細胞由来のコロニーを形成させる為に単核球の播種密度を最適化すること、（2）高い増殖能を持つMSCの割合を増やす為に培養期間を調整すること、（3）老化細胞を除去できる剥離処理の時間を設定することを提案する。

The objective of Chapter 1 of the present study was to evaluate the effect of heat-killed Lactobacillus sakei HS-1 (HK-LS HS-1) on the health and fecal bacteriological change of suckling Japanese Black calves as a supplement in milk replacers. To this end, they were randomly assigned to an HK-LS HS-1 supplement or a control without HK-LS HS-1 group in milk replacers. HK-LS HS-1 was administered from separation day to 3 weeks. Blood and fecal samples were examined. The result is glucose and vitamin A levels on day 7 were significantly higher in the supplement group than in the control group. No significant differences were observed in haptoglobin or serum amyloid A between the groups. The number of Escherichia coli in feces was lower in the control group than in the supplement group on day 21. No difference was observed in the number of Bifidobacteria, but that of lactic acid bacteria was significantly higher in the supplement group on day 21. The number of medications administered was significantly lower in the supplement group than in the control group during the experimental period. The results indicated that HK-LS HS-1 is potentially beneficial for improving intestinal microbes and reducing the number of medical treatments. In the second study, we evaluated the effects of supplementing cattle feed with difructose anhydride III (DFA III) by measuring urinary sterigmatocystin (STC) concentrations using 20 Japanese Black cattle aged 9–10 months from one herd. DFA III was supplemented for 2 weeks for 10 animals, and non-treated animals served as controls. STC concentration in the dietary feed was 0.06 mg kg−1(mixture of roughage and concentrate) at the beginning of the study (Day 0). The urine STC concentration was measured using liquid chromatography with tandem mass spectrometry 1 d prior to DFA 2 III administration, 9 and 14 d thereafter, and 9 d following supplementation cessation, concomitant with the measurement of serum amyloid A (SAA). The number of heifers in which STC was detected in the urine was low in the DFA III group compared to that in the control group on Day 9. After 9 d following supplementation cessation (Day 23), STC concentrations were significantly lower (P = 0.032) in the DFA III group than in the control group, although there was no difference in the number of heifers in which urinary STC was detected or in SAA concentrations between the two groups. Our findings demonstrate the effect of DFA III on reducing the urinary concentration of STC in Japanese Black cattle.

Aldosterone is a steroid hormone synthesized in the adrenal cortex and is part of the renin-angiotensin-aldosterone system (RAAS). It accelerates renal sodium retention and elimination of potassium through its action on the mineralocorticoid receptor (MR), and has a major role in regulating body fluid volume and blood pressure. Excessive secretion of aldosterone and activation of the MR cause cardiovascular inflammation, fibrosis and remodeling, and tubulointerstitial fibrosis and glomerular injury in the kidney. There are several reports on plasma aldosterone concentration (PAC) in healthy, chronic kidney disease (CKD), systemic hypertension, and chronic heart failure in cats and dogs. Measurement of urinary aldosterone/creatinine ratio has also been reported in cats and dogs. However, it has been suggested that measuring aldosterone in feline urine using the available methodology has limited or no utility in investigating feline hypertension associated with CKD. It may be important to evaluate PAC in cats and dogs with CKD associated with the activation of RAAS. On the other hand, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers suppress the RAAS during hypertensive, renal, and cardiac diseases in cats. The Randomized Aldactone Evaluation Study in humans showed that the aldosterone antagonist, spironolactone, reduced the mortality of patients with chronic heart failure who received ACEI and loop diuretics. Spironolactone also reportedly reduced the mortality rate in cats with congestive heart failure secondary to cardiomyopathy. Another selective aldosterone antagonist, eplerenone, not only antagonizes MR but also blocks the nongenomic effects of aldosterone in vascular tissues not susceptible to spironolactone. These effects of eplerenone may be more effective than spironolactone in treating hypertension due to vasoconstriction. Although eplerenone reduces mortality and hospitalization in human patients with chronic heart failure, there are no available reports on eplerenone’s use in feline practice. Since elevated PAC is a risk factor for kidney injury in humans, and MR antagonists are beneficial in rodent models of CKD and human patients, it was hypothesized that if an elevated PAC is detectable in the early stages of the disease in cats, the use of eplerenone may prolong lifespan. However, the relationship between PAC and the survival time in cats and dogs with CKD has not been investigated. Therefore, this study aimed to investigate PAC in cats and dogs with CKD, and evaluate the influence of high PAC on the survival time of CKD animals and the effect of treatment with eplerenone in CKD cats with high PAC. In chapter 1, PAC in cats with CKD was investigated retrospectively, and the survival time of cats with high PAC was evaluated. Furthermore, the effect of treatment with eplerenone on survival time in CKD cats with high PAC was examined prospectively. The eplerenone study was conducted including both cats with CKD only and CKD cats complicated cardiac disease or systemic hypertension. The PAC was measured retrospectively in blood samples obtained from 156 client-owned cats that visited a veterinary hospital. The cats were designated into 2 groups: clinically healthy (n = 101) and CKD (n = 55). The PAC was measured by solid-phase radioimmunoassay. Median (minimum–maximum) PAC in healthy cats was 97 (10–416) pg/mL and the upper limit (95th percentile) was 243 pg/mL. In the CKD group, PAC [126 (10–981) pg/mL] was significantly higher than in the clinically healthy group. In the CKD group as classified by the International Renal Interest Society (IRIS) stage, the PACs were higher in IRIS stage 2 than in the healthy group. Similarly, PACs in IRIS stage 3 and 4 cats were higher than in the healthy group. In cats with CKD, the survival time of those with high PAC (n = 16) (> 243 pg/mL) was significantly shorter than that of those (n = 39) with normal PAC. In cats with high PAC and CKD, eplerenone administration (2.5 to 5 mg/kg body weight; n = 8) prolonged significantly the survival compared to cats not receiving eplerenone (n = 18). These results indicated that PAC could be a prognostic marker of CKD in cats and that eplerenone may prolong the survival in cats with CKD and high PAC complicated with cardiac disease or hypertension. In chapter 2, PAC in dogs with CKD was investigated retrospectively, and the survival time of CKD dogs with high PAC was evaluated. PAC was measured in blood samples obtained from 145 client-owned dogs. The dogs were divided into two groups: clinically healthy (n = 106) and CKD (n = 39). In clinically healthy group, median (minimum–maximum) PAC was 56 (10–250) pg/mL, and the upper limit (95th percentile) was 182 pg/mL. PAC (median 69 pg/mL; range 10–553 pg/mL) in CKD group was significantly higher than in the healthy group. In the CKD group as classified by IRIS stage, PAC (median 97 pg/mL) in IRIS stage 2 and 3 was significantly higher than in the healthy group. A significant positive correlation between PAC and IRIS stage was observed in CKD dogs, suggesting that the lower survival rate in high PAC group may be related to severity of CKD. In dogs with CKD, the survival time of those with high PAC (n = 10) (> 182 pg/mL) was significantly shorter than that of those with normal PAC (n = 24). These results suggested that high PAC might indicate shorter survival time in dogs with CKD. In conclusion, this study revealed that both cats and dogs with CKD had significantly higher PAC than clinically healthy animals. In CKD, the survival time of cats and dogs with high PAC was significantly shorter than those with normal PAC. The use of eplerenone also significantly prolonged the survival of cats with high PAC in CKD complicated with cardiac disease or hypertension. This study proposes PAC as a prognostic marker of cats or dogs with CKD. Eplerenone may be useful in prolonging cats’ survival with high PAC in CKD complicated with cardiac disease or hypertension. However, further study on PAC level in CKD progression and treatment response in a larger population may be required. This study provided new information on the relationship between PAC and the survival of cats or dogs with CKD, and the effect of eplerenone treatment for the survival time of cats with high PAC and CKD.

Sleep is an essential physiological process for the human body. People spend about one-third of their lives sleeping. Both sleep duration and sleep quality are important to human health. Sleep quality describes how restful and restorative the sleep process is. Over 80 sleep disorders are known to affect sleep quality. Among them, sleep-related breathing disorder (SRBD) is the second factor. Sleep-related breathing disorders are sleep disorders in which breathing abnormalities occur during sleep. Abnormal snoring and respiratory arrest or abnormally low breathing during sleep reduce oxygen levels in the blood, increasing the risk of depression, cardiovascular disease, stroke and even death. Therefore, monitoring and analysis of respiration during sleep is gaining increasing importance in healthcare. Polysomnography (PSG) is considered the gold standard for diagnosing sleep disorders, but PSG is usually performed in an unfamiliar sleep laboratory under the supervision of a medical technician and is often worn with many sensors that interfere with sleep. It is often the case. This research group is developing a breathing sound measurement system that constantly monitors the quality of sleep in general home environment. This system can easily measure breath sounds during sleep all night with high accuracy without disturbing sleep. The purpose of this research is to develop a technique to classify patterns of breathing sounds and to analyze the quality of breathing in order to more accurately analyze the state of sleep from breath sound information. There are various patterns of sleep breath sounds, such as normal breath sounds and snoring, and abnormal breath sounds and snoring. To develop a method to classify these patterns, to develop an algorithm to calculate ventilation from breath sounds, to estimate the sleep apnea index (AHI), and to assess the quality of breathing during sleep. try. Specifically, the temporal feature waveform (TCW) is calculated after partly removing the noise of the breathing sounds of sleep with a band-pass filter. Based on the time feature waveform, a respiratory signal effective for analysis is extracted from low-level signals and phase-divided into a respiratory phase and an apnea or low signal. Mel-frequency cepstrum coefficients (MFCC) are then obtained for the respiratory phases, and an agglomerative hierarchical clustering (AHC) algorithm is applied to distinguish between normal/abnormal breathing, normal/abnormal snoring, and normal/abnormal breathing. , tossing and turning, etc., which are less relevant to breathing. The categorized breathing patterns are analyzed every 30 seconds and the relative tidal volume of the breath is calculated. In addition to verifying the effectiveness and accuracy of the technology and analysis method proposed in this study, a method of estimating the apnea syndrome index (AHI) and converting the ventilation volume into high, medium, and low levels, We propose a method to evaluate the quality of breathing in a patient and verify its effectiveness. This paper consists of six chapters, including an introduction and conclusion. Chapter 1 introduces the background and overview of this research. Chapter 2 describes a signal-processing technique for analyzing breath sounds during sleep and a method for classifying breathing patterns. Breathing sound data during sleep often includes disturbed breathing due to bruxism or body movement, ambient environmental noise, etc. In this chapter, the Time Characteristic Waveform (TCW) and the Characteristic Moment Waveform (CMW) are calculated for respiratory sound signals that have undergone preprocessing, such as filtering noise to preprocess the respiratory sounds, and the segmentation of inspiration and expiration is performed. The Mel-Frequency Cepstrum Coefficients (MFCC) are obtained for each respiratory cycle and applied as a feature vector to the Agglomerative Hierarchical Clustering (AHC) algorithm. This method is used to classify ordinary respiratory signals (normal and abnormal breathing, normal and abnormal snoring) from signals less relevant to respiration, such as tossing and turning and environmental noise. In Chapter 3, using the technology described in Chapter 2, breathing sound data during sleep are classified into apnea, hypopnea, normal breathing, abnormal breathing, normal snoring, and abnormal breathing for each 30-second frame. In addition, we describe a method for classifying events such as no snoring and rolling over and determining the respiratory state. In Chapter 4, we propose a method for estimating the apnea-hypopnea Apnea-Hypopnea Index (AHI) for classified abnormal breath sounds and low-level breath sound signals, compare it with the diagnostic results of PSG, and examine its validity. And verify usefulness. Chapter 5 describes a method for estimating ventilation volume from breath sounds. Because normal breath sounds are correlated with ventilation, this study used a quantitative approach to calculate normal breathing and normal snoring and a qualitative method to calculate apnea/hypopnea and abnormal breath sounds. We will propose and compare it with the diagnosis result of PSG and verify its validity. In Chapter 6, as an application development, an example of applying the breathing sound classification method proposed in this study to heart sound analysis is presented. Finally, we will explain the construction of a data collection distribution system for sharing auscultation data collected at different facilities and hospitals using blockchain technology. Chapter 7 presents the conclusions and prospects of this study.

To investigate whether dantrolene (DAN), cardiac ryanodine receptor (RyR2) stabilizer, improves impaired diastolic function in an early pressure-overloaded hypertrophied heart, pressure-overload hypertrophy was induced by transverse aortic constriction (TAC) in mice. Wild-type (WT) mice were divided into four groups: sham-operated mice (Sham), sham-operated mice treated with DAN (DAN+Sham), TAC mice (TAC), and TAC mice treated with DAN (DAN+TAC). The mice were then followed up for 2 weeks. Left ventricular (LV) hypertrophy was induced in TAC, but not DAN+TAC mice, 2 weeks after TAC. There were no differences in LV fractional shortening among the four groups. Catheter tip micromanometer showed that the time constant of LV pressure decay, an index of diastolic function, was significantly prolonged in TAC but not in DAN+TAC mice. Diastolic function was significantly impaired in TAC, but not in DAN+TAC mice as determined by cell shortening and Ca^{2+} transients. An increase in diastolic Ca^{2+} leakage and a decrease in calmodulin (CaM) binding affinity to RyR2 were observed in TAC mice, while diastolic Ca^{2+} leakage improved in DAN+TAC mice. Thus, DAN prevented the progression of hypertrophy and improved the impairment of LV relaxation by inhibiting diastolic Ca^{2+} leakage through RyR2 and the dissociation of CaM from RyR2.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by a single point mutation in the cardiac type 2 ryanodine receptor (RyR2). Using knock-in mouse (KI) model (R2474S/+), we previously reported that a single point mutation within the RyR2 sensitized the channel to agonists, primarily mediated by defective inter-domain interaction within the RyR2 and subsequent dissociation of calmodulin (CaM) from the RyR2. Here, we examined whether CPVT can be genetically rescued by enhancing the binding affinity of CaM to the RyR2. We first determined whether there was a possible amino-acid substitution within the CaM-binding domain in the RyR2 (3584-3603) that can enhance its binding affinity to CaM, and found that V3599K substitution showed the highest binding affinity of CaM to CaM-binding domain. Hence, we generated a heterozygous KI mouse model (V3599K/+) with a single amino acid substitution in the CaM-binding domain of the RyR2, and crossbred it with the heterozygous CPVT –associated R2474S/+ KI mouse to obtain a double heterozygous R2474S/V3599K KI mouse model. The CPVT phenotypes, bidirectional or polymorphic ventricular tachycardia, were inhibited in the R2474S/V3599K mice. Thus, enhancement of the CaM binding affinity of the RyR2 is essential to prevent CPVT-associated arrhythmogenesis.

1907年のイギリスのスタインをはじめ、列強各国の探検隊が次々と敦煌を訪れた。敦煌文物の発見・流出に伴い、「敦煌学」「西域熱」が誕生し、学界の関心を集めてきた。仏教出身の武田泰淳も長い間にわたってスタインの著作（Ruins of Desert Cathay、Serindiaなど）を含む敦煌資料を耽読し、その分野に進出してみた。本論は武田と敦煌との関係を切口として、日本近代文学館に所蔵されている「武田泰淳コレクション」の中の未発表資料を参考にして、武田文学における唯一の敦煌題材小説「流沙」の典拠資料を整理し武田の英語力を確認した上で、典拠と小説との比較を行い、「節ごと」、「人物ごと」、「全体」という三つの方面から武田泰淳の言う「換骨奪胎」の方法（典拠の利用法）を分析した。

人口減少社会の到来により，特に地方において，適正規模での学校運営が難しい過小規模や極小規模の学校が増加傾向にある．このような小規模校では，きめ細やかな指導等が行える一方で，人間関係が固定化しがちであったり，多様な意見や考え方に触れることが少なくなったり等，教育上の課題を抱えている．その解決策の１つとして，複数校の児童生徒が1つの学校に集まって合同授業が実施されているが，時間的・金銭的な問題などから実施回数が制限されるケースが多い．この合同授業を補う形で，日進月歩の勢いで進歩しているICT技術を活用した遠隔合同授業の取組みが期待され，教育実践が進められてきている．そこで本研究では，小規模校・少人数学級における遠隔合同授業を対象にして，学習者の学習活動と教員の教授活動を支援するための遠隔合同授業支援環境を研究開発する．具体的には，学校のネットワークの問題や，対面遠隔の学習者を見とりながら遠隔合同授業を進める教員の負荷を踏まえて，ビデオコミュニケーション機能や遠隔合同授業をシームレスに支援する授業支援機能を有した「つながる授業アプリ」をアジャイル型開発手法によって実装した．さらに，「つながる授業アプリ」の操作・機能評価を行って修正事項を整理して，改善を行った事項について報告する．